SI 201
Alternative Names: SI-201; SIRPant-T™Latest Information Update: 12 Jun 2023
At a glance
- Originator SIRPant Immunotherapeutics
- Class Antineoplastics; Immunotherapies; T lymphocyte cell therapies
- Mechanism of Action Immunologic cytotoxicity
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Research Cancer